Alendronate Alternatives Compared
| Alendronate | Prolia | Fosamax |
|
|---|
| Alendronate | Prolia denosumab | Fosamax alendronate |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Alendronate helps to reduce the risk of fracture in people with osteoporosis and some other bone conditions. Dosage instructions, including remaining upright for at least 30 minutes and taking with a... View more |
Prolia is an injection that can be self-administered once every six months for the treatment of osteoporosis. It has been associated with an increased risk of fractures on discontinuation. Prescribed... View more |
Fosamax helps to reduce the risk of fracture in people with osteoporosis and some other bone conditions. Dosage instructions, including remaining upright for at least 30 minutes and taking with a... View more |
Choose a suggestion below |
|||||||||||||||||||||||
| More about Alendronate | More about Prolia (denosumab) | More about Fosamax (alendronate) | ||||||||||||||||||||||||
| Generic Status | ||||||||||||||||||||||||||
|
No lower-cost generic available |
||||||||||||||||||||||||||
| Availability | ||||||||||||||||||||||||||
|
Prescription only |
Prescription only |
Prescription only |
||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Alendronate has an average rating of 2.2 out of 10 from a total of 140 ratings on Drugs.com. 12% of reviewers reported a positive effect, while 85% reported a negative effect. |
Prolia has an average rating of 2.7 out of 10 from a total of 318 ratings on Drugs.com. 14% of reviewers reported a positive effect, while 79% reported a negative effect. |
Fosamax has an average rating of 2.4 out of 10 from a total of 60 ratings on Drugs.com. 14% of reviewers reported a positive effect, while 84% reported a negative effect. |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Side Effects | ||||||||||||||||||||||||||
|
Commonly reported side effects include: decreased serum calcium, decreased serum phosphate. See the full alendronate side effects document. |
See the full Prolia side effects document. |
Common side effects include: decreased serum calcium, decreased serum phosphate. See the full Fosamax side effects document. |
||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all alendronate prices |
View all Prolia prices |
View all Fosamax prices and generic prices |
||||||||||||||||||||||||
| Dosage Form(s) Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Binosto, Fosamax | Other denosumab brands include: Xgeva | Other alendronate brands include: Binosto | ||||||||||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
|
N/A |
609.6 hours |
N/A |
||||||||||||||||||||||||
| CSA Schedule** View glossary of terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full Pregnancy Warnings document. |
Category X
Not for use in pregnancy
See the full Pregnancy Warnings document. |
Category C
Risk cannot be ruled out
See the full Pregnancy Warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 106 drugs are known to interact with alendronate:
|
A total of 249 drugs are known to interact with Prolia:
|
A total of 106 drugs are known to interact with Fosamax:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
September 29, 1995 |
June 01, 2010 |
September 29, 1995 |
||||||||||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.